A number of other analysts have also issued reports on the stock. Citigroup Inc. raised their target price on shares of Atyr Pharma from $3.00 to $4.00 and gave the stock a neutral rating in a research report on Tuesday, August 16th. Zacks Investment Research upgraded shares of Atyr Pharma from a hold rating to a buy rating and set a $4.00 target price on the stock in a research report on Tuesday, August 16th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Atyr Pharma from $15.00 to $10.00 and set an overweight rating on the stock in a research report on Thursday, August 11th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Atyr Pharma has an average rating of Hold and a consensus target price of $6.50.
Shares of Atyr Pharma (NASDAQ:LIFE) opened at 2.89 on Thursday. The firm has a 50-day moving average price of $3.12 and a 200-day moving average price of $3.24. The stock’s market cap is $68.55 million. Atyr Pharma has a 12 month low of $2.48 and a 12 month high of $13.26.
Atyr Pharma (NASDAQ:LIFE) last announced its earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.06. Equities analysts expect that Atyr Pharma will post ($2.56) EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new position in shares of Atyr Pharma during the second quarter worth $101,000. A.R.T. Advisors LLC raised its position in shares of Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock worth $108,000 after buying an additional 18,410 shares during the period. Bridgeway Capital Management Inc. bought a new position in shares of Atyr Pharma during the second quarter worth $133,000. Jackson Park Capital LLC bought a new position in shares of Atyr Pharma during the second quarter worth $183,000. Finally, State Street Corp raised its position in shares of Atyr Pharma by 51.8% in the first quarter. State Street Corp now owns 68,285 shares of the company’s stock worth $270,000 after buying an additional 23,290 shares during the period. Institutional investors own 44.75% of the company’s stock.
Atyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.